Ascentage Pharma Group International (AAPG) Cash & Equivalents (2022 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Cash & Equivalents for 4 consecutive years, with $168.6 million as the latest value for Q4 2025.
- For Q4 2025, Cash & Equivalents rose 35.6% year-over-year to $168.6 million; the TTM value through Dec 2025 reached $168.6 million, up 35.6%, while the annual FY2025 figure was $171.0 million, 33.89% up from the prior year.
- Cash & Equivalents hit $168.6 million in Q4 2025 for Ascentage Pharma Group International, up from $124.3 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $189.2 million in Q4 2022 and bottomed at $124.3 million in Q4 2024.
- Average Cash & Equivalents over 4 years is $156.6 million, with a median of $156.4 million recorded in 2025.
- Year-over-year, Cash & Equivalents dropped 23.8% in 2023 and then skyrocketed 35.6% in 2025.
- Ascentage Pharma Group International's Cash & Equivalents stood at $189.2 million in 2022, then decreased by 23.8% to $144.2 million in 2023, then fell by 13.76% to $124.3 million in 2024, then surged by 35.6% to $168.6 million in 2025.
- According to Business Quant data, Cash & Equivalents over the past three periods came in at $168.6 million, $124.3 million, and $144.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.